Effects of cannabis oil in palliative care of recurrent ovarian cancers patients

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

TCTR

Registry ID

TCTR20241117002

Enrollment

Registered

2024-11-17

Start date

2024-06-03

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent high grade serous ovarian cancers epithelial ovarian cancer recurrence high grade serous

Interventions

THC/CDB oil 1:1 (27/25 mg/ml) 1 drop sublingual once a day,THC/CDB oil 1:1 (27/25 mg/ml) 1 drop sublingual once a day plus palliative chemotherapy

Experimental Drug,Active Comparator Drug

THC/CBD oil only,THC/CBD oil plus chemotherapy

Eligibility

Sex/Gender

Female

Age

25 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Recurrent epithelial ovarian cancers with platinum refractory/resistant 2. Age > 25 years 3. Thai read/write ability 4. Ability to use sublingual drop medication

Exclusion criteria

Exclusion criteria: 1. Contraindicated for cannabis oil 2. Unable to use sublingual drop medication 3. Severe other disease such as uncontrolled DM, HT, thyrotoxicosis or renal insufficiency grade 3-4 4. Other herbal use 5. Use of fluoxetine, rifampicin, carbamazepine, warfarin, clobazam, fluoroquinolones and dihydropyridines

Design outcomes

Primary

Measure	Time frame
Side effects 6 months Fisher's exact test	—

Secondary

Measure	Time frame
Survival 6 months Kaplan-Meier	—

Countries

Thailand

Contacts

Public ContactBandit Chumworathayi

Khon Kaen University

bunchu@kku.ac.th0818733327

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026